Drug Profile
Betamethasone valerate foam - Stiefel Laboratories
Alternative Names: 0.12% betamethasone 17-α-valerate; 0.12% betamethasone valerate - Stiefel; Betamousse; LuxiqLatest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Soltec Research; Stiefel Laboratories
- Developer Mipharm; Stiefel Laboratories
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Fluorinated steroids; Glucocorticoids; Small molecules
- Mechanism of Action Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Atopic dermatitis; Psoriasis; Seborrhoeic dermatitis; Skin disorders
Most Recent Events
- 22 Jul 2009 Stiefel Laboratories has been acquired by GlaxoSmithKline
- 28 Dec 2006 Connetics Corporation has been acquired and merged into Stiefel Laboratories
- 22 Oct 2004 Celltech Pharmaceuticals has terminated its UK co-promotion rights for Luxiq® effective 31 March 2005